Wednesday, November 18, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Cardiff Oncology Shares Gain Favor as Analysts Revise Forecasts

Jackson Burston by Jackson Burston
April 1, 2026
in Analysis, Earnings, Pharma & Biotech, Turnaround
0
Cardiff Oncology Stock
0
SHARES
56
VIEWS
Share on FacebookShare on Twitter

Market experts are growing more optimistic about Cardiff Oncology’s financial trajectory. Following the biotechnology firm’s stronger-than-anticipated performance in February, analysts have now moved to upgrade their earnings projections for the start of fiscal year 2026.

Financial Estimates Revised Upward

In a recent research note dated March 26, the team at Noble Financial updated their model for Cardiff Oncology’s first quarter. The firm now anticipates a per-share loss of $0.14, a notable improvement from its previous forecast of a $0.19 loss. This adjustment comes directly on the heels of the company’s February quarterly report, which delivered a positive surprise by exceeding consensus estimates for both revenue and earnings.

Noble Financial has maintained its “Outperform” rating on the equity. While the analysts project a full-year 2026 net loss of $0.64 per share, they see significant upside potential, assigning a price target of $12.00. This target implies substantial growth from the current trading level of approximately $1.55 per share.

Should investors sell immediately? Or is it worth buying Cardiff Oncology?

Market Context and Performance

Currently valued with a market capitalization of around $106 million, Cardiff Oncology’s stock has experienced considerable volatility. Over the preceding 52-week period, its shares have traded within a wide band, reaching a low of $1.48 and a high of $4.56.

The foundation for the renewed analyst confidence was laid by recent revenue figures. The company reported sales of $0.24 million, nearly double the $0.13 million that market watchers had expected. The stark gap between the present share price and the elevated targets set by research firms underscores the market’s focus on upcoming clinical trial data expected later this year.

The broader analyst consensus currently categorizes the stock as a “Moderate Buy,” with the average price objective standing at $10.10.

Ad

Cardiff Oncology Stock: Buy or Sell?! New Cardiff Oncology Analysis from November 18 delivers the answer:

The latest Cardiff Oncology figures speak for themselves: Urgent action needed for Cardiff Oncology investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 18.

Cardiff Oncology: Buy or sell? Read more here...

Tags: Cardiff Oncology
Jackson Burston

Jackson Burston

Related Posts

SAP Stock
Analysis

SAP’s Buyback Machine Grinds On, But the Analyst Chorus Is Turning Sour

September 7, 2026
Münchener Rück Stock
Analysis

Munich Re’s Monte Carlo Warning Collides With Wall Street’s Widest Analyst Split in Years

September 7, 2026
Nvidia Stock
AI & Quantum Computing

Nvidia’s Insider Sales and $12.9 Billion Acquisition Paint a Portrait of a Company in Overdrive

September 7, 2026
Next Post
Teradyne Stock

Teradyne Shares Surge Following Analyst Upgrade and Strong AI-Driven Results

Tilray Stock

Tilray's Strategic Pivot Faces Crucial Earnings Test

T1 Energy Stock

Leadership Reshuffle at T1 Energy Amidst Financial Update and Share Price Weakness

Recommended

Mirum Pharmaceuticals Stock

Mirum Pharmaceuticals: A Pivotal Year of Clinical Catalysts and Financial Milestones

8 months ago
Marvell Technology Stock

Marvell Technology’s AI Business Fuels Record Quarter Amid Mixed Segment Performance

1 year ago
Ondas Holdings Stock

Ondas Holdings: Can New Contracts Reignite Its Stalled Momentum?

12 months ago
Block Stock

A Tale of Two Titans: Block and PayPal’s Divergent Fintech Paths

1 year ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum DroneShield Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Bitcoin Slips Below $70,000, and a Samsung Rumor Lifts Modine

Huang Exits, Cisco Reports: Who Actually Gets Paid for AI

The AI Rebound Gets an Audit: Who Earns, Who Borrows

A Hot CPI Reading Stalls the Rebound and Puts a December Hike in Play

Cash Over Stories: Take-Two, Cisco and Nvidia Face Their Tests

Four Down Weeks for the Nasdaq, and Consumer Stocks Quietly Cash In

Trending

Home Depot Stock
Newsletter

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

by Stephanie Dugan
November 17, 2026
0

Dear readers, Home Depot did what it was supposed to do on Tuesday morning and got little...

Bitcoin Stock

Rotation, Not Panic: Retailers Test Where Tech’s Money Went

November 16, 2026
Cisco Stock

At 5.15%, the 10-Year Treasury Picks the Winners

November 14, 2026
Bitcoin Stock

Bitcoin Slips Below $70,000, and a Samsung Rumor Lifts Modine

November 13, 2026
Cisco Stock

Huang Exits, Cisco Reports: Who Actually Gets Paid for AI

November 12, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers
  • Rotation, Not Panic: Retailers Test Where Tech’s Money Went
  • At 5.15%, the 10-Year Treasury Picks the Winners

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com